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ABSTRACT 
 
Although non-alcoholic fatty liver disease (NAFLD) is currently the most common form of 
chronic liver disease there is no pharmacological agent approved for its treatment. Since 
peroxisome proliferator-activated receptors (PPARs) are closely associated with hepatic lipid 
metabolism, they seem to play important roles in NAFLD. However, the effects of PPAR 
agonists on steatosis that is a common pathology associated with NAFLD, remain largely 
controversial. In this study, the effects of various PPAR agonists, i.e. fenofibrate, bezafibrate, 
troglitazone, rosiglitazone, muraglitazar and tesaglitazar on oleic acid-induced steatotic 
HepaRG cells were investigated after a single 24-hour or 2-week repeat treatment. Lipid 
vesicles stained by Oil-Red O and triglycerides accumulation caused by oleic acid overload, 
were decreased, by up to 50%, while fatty acid oxidation was induced after 2-week co-
treatment with PPAR agonists. The greatest effects on reduction of steatosis were obtained 
with the dual PPARa/γ agonist muraglitazar. Such improvement of steatosis was associated 
with up-regulation of genes related to fatty acid oxidation activity and down-regulation of 
many genes involved in lipogenesis. Moreover, modulation of expression of some nuclear 
receptor genes, such as FXR, LXRα and CAR, which are potent actors in the control of 
lipogenesis, was observed and might explain repression of de novo lipogenesis. Conclusion: 
Altogether, our in vitro data on steatotic HepaRG cells treated with PPAR agonists correlated 
well with clinical investigations, bringing a proof of concept that drug-induced reversal of 
steatosis in human can be evaluated in in vitro before conducting long-term and costly in vivo 
studies in animals and patients. 
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INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is currently the most common form of chronic 
liver disease and is strongly associated with obesity, type 2 diabetes and insulin resistance 
(Caldwell and Argo, 2010 ; Lomonaco et al., 2013). Considered as the hepatic manifestation 
of the metabolic syndrome, NAFLD encompasses a wide spectrum of clinical-histological 
disturbances ranging from simple triglycerides accumulation in hepatocytes (hepatic steatosis) 
to hepatic steatosis with inflammation [non-alcoholic steatohepatitis (NASH)], fibrosis, 
cirrhosis and in severe cases, hepatocarcinoma. 
 
The pathogenesis of fatty liver is intimately related to derangements in nutrient metabolism 
and energy homeostasis, which are tightly regulated by endocrine, paracrine, and autocrine 
signals that control the expression and activity of key metabolic enzymes by transcriptional 
and post-transcriptional mechanisms. Peroxisome proliferator-activated receptors (PPARs) 
have recently emerged as a master class of ligand-activated transcription factors involved in 
maintaining lipid homeostasis and energy balance, as well as a variety of other biological 
processes. PPARs comprise three subtypes: PPARa (NR1C1), PPARβ/δ (NR1C2) and 
PPARγ (NR1C3), that each mediates distinct physiological effects on lipid metabolism and 
glucose homeostasis (Michalik et al., 2006). PPARa plays a pivotal role in fatty acid 
catabolism in liver by transcriptionally up-regulating the expression of some of the key genes 
involved in fatty acid oxidation (FAO) (Reddy and Hashimoto, 2001). PPARβ/δ is a powerful 
metabolic regulator expressed ubiquitously that also exerts key functions in liver by 
enhancing fatty acid catabolism (Barish et al., 2006). PPARγ is mainly expressed in adipose 
tissue and is known to be a regulator of lipid metabolism and glucose homeostasis.  
Synthetic PPAR agonists represent attractive drug targets for the management of NAFLD and 
NASH. PPARa activators, typified by fibrates, are used to treat dyslipidemia while PPARg 
ligands, such as thiazolidinediones, act as insulin sensitizers in type 2 diabetes mellitus. Both 
agonist classes have been reported to attenuate NASH. Thus, fibrates, such as fenofibrate, 
have been shown to reduce and/or prevent fatty liver in various experimental models (Nagai 
et al., 2002; Ye et al., 2002). Their effects have been attributed to an increase in hepatic FAO 
activity, however some discrepancies have been observed in human NASH treated with 
fibrates. A 12-month treatment of patients with NASH and elevated triglycerides with 
clofibrate had no impact on liver enzyme elevation or triglyceride levels (Laurin et al., 1996). 
In fact, the human liver expresses relatively low levels of PPARa and PPARa activation, and 
has little impact on FAO in contrast to its rodent counterpart (Kane et al., 2006). The PPAR 
pan-agonist, bezafibrate, which modulates FAO by influencing both PPARα and PPARδ, was 
also found to reduce hepatic steatosis (Nagasawa et al., 2006) and improve NASH (Nagasawa 
et al., 2006; Lim et al., 2009). 
The effects of PPARg agonists on steatosis and NAFLD are also controversial. While PPARg 
expression and activity are low in normal liver they are usually increased in steatotic liver of 
both animals (Kim et al., 1998) and humans (Gavrilova et al., 2003). Nevertheless, although 
PPARg is considered as a steatogenic factor, its activation is a putative target for the treatment 
of NAFLD. Indeed, thiazolidinediones (e.g. pioglitazone and rosiglitazone) and metformin are 
the principal insulin sensitizing agents employed in the management of NAFLD for their 
capacity to reduce amino-transferase levels and to improve histological grading (Balas et al., 
2007), probably as a consequence of their primary insulin-sensitizing effects on adipose tissue 
(Tanaka et al., 2003). 
Dual PPARa/g agonists have also been considered to be attractive as therapy for NAFLD, 
NASH and the metabolic syndrome as they have been reported to have the potential to 
improve insulin sensitivity and decrease circulating triglycerides in animals. However, the 
first molecules, muraglitazar and tesaglitazar, have been withdrawn from phase III clinical 
trials due to increased incidence of cardiac and renal toxicities (Hamren et al., 2008; Rubin et 
al., 2009). 
 
With the global prevalence of metabolic syndrome, obesity and NAFLD in recent years, there 
is an increasing need to better understand the role of PPAR agonists on the etiology of fatty 
liver disease. The aim of this study was to analyze the effects of the different types of PPAR 
agonists (glitazones, glitazars and fibrates) on steatosis induced by oleic acid overload in 
differentiated human HepaRG cells after acute and repeat treatments (Antherieu et al., 2011). 
A decrease in triglycerides content associated with an increase in FAO-related gene 
expression and activity was observed with all agonists after 14-day repeat exposure. The 
strongest effects were obtained after treatment with the dual PPARa/g agonist muraglitazar.  
MATERIAL AND METHODS 
 
Chemicals. Troglitazone, rosiglitazone, muraglitazar and tesaglitazar were provided by the 
Servier Chemical Department. Fenofibrate, bezafibrate and oleic acid (OA) were purchased 
from Sigma (St. Quentin Fallavier, France). [U-
14
C]-palmitic acid was from Perkin Elmer 
(Boston, MA).  
HepaRG cells. The untransformed human HepaRG cell line is derived from a human 
cholangiohepatocarcinoma. The cells used in this study were from cells stored frozen at 
passage 10 and experiments were performed between passages 13 and 18. Briefly, HepaRG 
cells were usually seeded at a density of 2.6 x10
4
 cells/cm
2
 in the Williams' E medium 
supplemented with 10% fetal calf serum, 100 units/mL penicillin, 100 μg/mL streptomycin, 5 
μg/mL insulin, 2 mM glutamine and 50 µM hydrocortisone hemisuccinate (Gripon et al., 
2002). After two weeks, HepaRG cells were transferred to the same medium supplemented 
with 2% dimethylsulfoxide (DMSO) for further two weeks in order to obtain confluent 
differentiated cultures containing both hepatocyte-like and progenitors/primitive biliary-like 
cells (around 50% of each type) (Cerec et al., 2007). In the presence of DMSO the levels of 
certain functions, in particular those of some major cytochromes P450 such as CYP3A4, are 
markedly increased (Aninat et al., 2006; Kanebratt and Andersson, 2008; Antherieu et al., 
2010).  
Chemical treatments. The PPAR agonists and OA were dissolved manually in 
dimethylsulfoxide. HepaRG cell cultures were first exposed to 250 µM OA for 24 hours, then 
continuously to OA either alone or together with each PPAR agonist for 24 hours or repeated 
treatments every 2-3 days for 14 days (Figure 1). DMSO dilutions were made from a 100% 
DMSO solution. At least three independent experiments were performed in triplicates. 
Cell viability. Cytotoxicity was evaluated using the methylthiazoletetrazolium (MTT) 
colorimetric assay. After treatment, medium was removed and serum-free medium containing 
0.5 mg/mL MTT was added to each well and incubated for 2 hours at 37°C. After removal of 
the incubation solution, water-insoluble formazan was dissolved in DMSO and absorbance 
was measured at 550 nm.  
Oil Red O staining and lipid droplets analysis by cell imaging. Neutral lipid accumulation 
was determined by Oil Red O staining, which allows detection of triglycerides and cholesterol 
esters. A stock solution of Oil Red O was prepared in isopropanol (0.5:100). After each 
treatment, cells were incubated for one hour with Oil Red O-saturated solution 
(isopropanol:water, 3:2) and then observed under phase-contrast microscopy. To quantify 
lipid accumulation, Oil Red O-stained lipid droplets were analyzed by cell imaging. Areas of 
stained droplets were determined by the Image J software and normalized by the areas of 
hepatocyte clusters. 
Triglycerides quantification. Triglycerides were extracted using an organic solvent 
chloroform/methanol (2/1 v/v). A serum triglycerides determination kit (Sigma) was used for 
quantification, using a spectrophotometer with absorbance at 550 nm according to the 
manufacturer’s instructions.  
Real time-quantitative polymerase chain reaction analysis (RT-qPCR). Total RNA was 
extracted
 
from 10
6
 HepaRG cells using the SV total RNA isolation system (Promega). RNAs 
were reverse-transcribed into cDNA and RT-qPCR was performed using a SYBR Green mix 
and a Step One plus equipment (Applied Biosystems). Primer sequences are listed in Table 1.  
 
Fatty acid oxidation. HepaRG cells were incubated with a medium containing 0.5 mM L-
carnitine, 10% fat-free bovine serum albumin and [U-
14
C]-palmitic acid (final concentration, 
1 mM; 0.05 μCi/mL). The reaction was carried out for 90 min at 37°C. After addition of 
perchloric acid (final concentration, 3%) and centrifugation (4000g; 10 min) an aliquot of the 
supernatant was sampled and counted for [
14
C]-labelled acid-soluble β-oxidation products 
(Fisch et al., 1996). 
Statistical analysis. Each value corresponded to the mean ±
 
standard error of mean (S.E.M) 
of three independent experiments in triplicates. The Mann-Whitney U
 
test was applied to 
compare data between OA- or drug-treated cell cultures and their control counterparts. Data 
were considered significantly different
 
when p<0.05. 
RESULTS 
 
Cytotoxic effects of PPAR agonists in steatotic HepaRG cells 
Preliminary experiments were performed to assess cytotoxicity of the different PPAR agonists 
in steatotic HepaRG cells over a 14-day period. In order to induce vesicular steatosis, 
HepaRG cells were exposed to 250 µM OA for 24 hours (Antherieu et al., 2011) prior to co-
treatment with PPAR agonists. Noticeably, when OA-overloaded HepaRG cells were 
maintained in culture without repeat exposure to the fatty acid, vesicular steatosis disappeared 
within 5 days; consequently effects of PPAR agonists were investigated with simultaneous 
addition of OA during the 14-day treatment.  
Neither cellular morphological alterations nor loss of cell viability were observed in untreated 
cultures over a 14- day period. OA alone did not cause any cytotoxicity after 1-day exposure 
while after a 14-day treatment slight toxicity was observed not exceeding a 12% decrease in 
MTT values. All compounds were added to the cultures at a high concentration 
corresponding to IC10, i.e. the concentration that caused 10% loss of cell viability in OA-
overloaded HepaRG cells after 14-day treatment (Figure 2). Accordingly, examination of the 
cultures under phase-contrast microscopy did not reveal marked cellular morphological 
alterations after a 14-day treatment whatever the PPAR agonist tested. Consequently, 25 µM 
fenofibrate and bezafibrate, 40 µM troglitazone, 50 µM rosiglitazone and muraglitazar and 
300 µM tesaglitazar were used for further experiments.  
Oil Red O staining and quantification of lipid droplets by cell imaging 
Cells were first exposed to OA for 24h and then co-treated with troglitazone, rosiglitazone, 
muraglitazar, tesaglitazar, fenofibrate and bezafibrate for either 1 or 14 days and neutral lipids 
(triglycerides and cholesterol esters) were stained by Oil Red O. Cells were examined under 
phase-contrast microscopy and photographed (Figure 3A) before quantification of 
intracellular Oil Red O accumulation by cell imaging (Figure 3B). As previously reported 
(Antherieu et al., 2011), numerous vesicles stained with Oil Red O were observed in the 
cytoplasm of HepaRG hepatocytes after 1- and 14-day incubation with OA under light 
microscopy. After 1-day co-treatment with PPAR agonists, intracellular distribution of lipid 
vesicles was not affected while their intracytoplasmic surface appeared to be reduced by about 
50% after 14 days with rosiglitazone, muraglitazar, tesaglitazar, fenofibrate and bezafibrate. 
By contrast, troglitazone did not cause detectable variations in intracytoplasmic lipid staining 
when compared with cultures incubated with OA alone. 
 
Triglycerides quantification  
Triglycerides levels were determined by spectrophotometry (Figure 4). OA induced a 2-fold 
increase in triglycerides after 1 day and no further change was observed over a 14-day period. 
Co-treatment with PPAR agonists for 1 day did not show significant difference compared to 
untreated OA-overloaded cells. After repeat exposure, a slight decrease in triglycerides 
content was observed with troglitazone whereas more pronounced reduction was 
demonstrated with the other PPAR agonists, especially rosiglitazone and muraglitazar. 
Indeed, rosiglitazone and muraglitazar decreased triglycerides levels to approximately 50 and 
60 % of the values measured in the OA-treated cultures respectively.   
 
Induction of fatty acid oxidation 
Since FAO was described as an important pathway involved in the modulation of steatosis, 
the effects of PPAR agonists on FAO activity were also assessed (Figure 5). Cells were 
incubated with [
14
C]-palmitate and FAO was estimated by measuring [
14
C]-labelled acid-
soluble ß-oxidation products. OA overload did not significantly modulate FAO activity 
whatever the treatment duration. No effect of PPAR agonists was also noticed after 1-day 
treatment. By contrast, FAO activity was increased after 14-day repeat treatment with all 
PPAR agonists. The highest increases were obtained with muraglitazar, bezafibrate and 
rosiglitazone, reaching 1.7-fold with muraglitazar relative to untreated control. In addition, a 
dose-response analysis of the effects of rosiglitazone and muraglitazar on fatty acid oxidation 
activity was performed and demonstrated that the highest effects were obtained with the 
highest concentration of each agonist (data not shown).  
mRNA expression modulation of key genes involved in lipid metabolism  
In order to better investigate the mechanisms involved in steatosis reduction in OA-
overloaded HepaRG cells, changes in the expression of several genes, which are key players 
in lipid metabolism were examined by RT-qPCR after 1- and 14-day treatments with PPAR 
agonists (Table 2). These genes are involved in de novo lipogenesis (ELOVL6, FASN, 
PPARG, SCD1, SREBP1 and THRSP), FAO and mitochondrial biogenesis (ACADL, 
ACOX1, CPT1A, CPT2, ECH1, CYP4A11, HADHA and PPARA), lipid hydrolysis and 
formation of lipid droplets (ADFP, PLIN4 and LPL), lipoprotein synthesis (APOC3), nuclear 
receptors (LXR, FXR, PXR and CAR) as well as other liver functions (ALB and CYP2B6).   
As previously reported, CTP1A, ADFP and PLIN4 were overexpressed and THRSP was 
repressed after 1-day and 14-day OA-overload (Antherieu et al.,2011). Almost all genes were 
modulated by one or more PPAR agonists at least at one time-point after 1- and 14-day co-
treatments with OA. A noticeable up-regulation of the genes related to FAO, mitochondrial 
biogenesis, lipid hydrolysis and formation of lipid droplets was observed after 1-day 
treatment, with the highest fold changes after muraglitazar exposure, especially for ACOX1, 
CPT1A, CPT2, ECH1, ADFP and PLIN4. After 14-day treatment, expression of these genes 
remained most important for muraglitazar and rosiglitazone. Deregulated genes related to de 
novo lipogenesis, except THRSP, were also overexpressed after 1 day whereas they were 
mostly unchanged or even decreased after 14 days, for each PPAR agonist. It is noteworthy 
that APOC3, the main endogenous inhibitor of LPL, was overexpressed by rosiglitazone and 
the two glitazars after 14-day treatment.  
To understand how modulation of related FAO and de novo lipogenesis genes might occur, 
expression of some nuclear receptors, such as LXR, FXR, PXR and CAR, were also 
investigated. After 1 day, LXRα, the main inducer of SREBP1, was overexpressed by all the 
test compounds, especially the two glitazones. By contrast, after 14 days, LXRα expression 
was dramatically decreased by fenofibrate, troglitazone and tesaglitazar. The second isoform 
LXRβ did not show any significant change after either 1- or 14-day treatments (data not 
shown). The nuclear receptor FXR was also up-regulated after 1 day by bezafibrate and 
muraglitazar and it was still significantly overexpressed after 14 days by muraglitazar only.  
PXR and CAR mRNA levels were similarly measured, because of their potential role in the 
regulation of lipid metabolism. After 1-day or 14 days treatments PXR expression was either 
unchanged or slightly down- or up-regulated. CAR expression was up-regulated after 1 day 
by both glitazones, fibrates, and muraglitazar whereas after 14 days, it was still deregulated 
only by muraglitazar, with a 2.2-fold increase relative to untreated control.  
ALB and CYP2B6 genes were also found to be modulated. After a 14-day treatment albumin 
transcripts were augmented with both glitazones and glitazars while they were decreased by 
fenofibrate and bezafibrate. As expected (Rogue et al.,2011), CYP2B6 was specifically 
overexpressed by the two glitazones at both time-points.  
 DISCUSSION 
 
Although NAFLD is currently the most common form of chronic liver disease there is 
currently no marketed drug for its treatment (Lomonaco et al., 2013). As PPAR agonists 
influence hepatic lipid homeostasis and energy balance, they represent an attractive target for 
the development of novel drug therapies in the management of NAFLD. However, although 
activation of the three classes of PPARs by synthetic ligands has been shown to reduce 
hepatic steatosis in rodents, discrepancies still remain with data obtained from clinical studies 
in humans (Laurin et al., 1996; Mahady et al., 2011; Lomonaco et al., 2013). In the current 
work, we showed that repeat activation of PPARs by several agonists resulted in reduction of 
steatosis using fatty acid-overload human HepaRG cells (Antherieu et al., 2011). 
Improvement of OA-induced steatosis was evidenced by a decrease in intracellular lipid 
droplets and triglycerides content, induction of FAO and overexpression of genes related to 
FAO and mitochondrial biogenesis after a 2-week treatment. The most potent effects were 
obtained with the dual PPAR agonist muraglitazar and to a lesser extent with rosiglitazone. 
The choice of PPAR agonists concentrations was based on IC10 values determined by the 
MTT test in 14-day cultures; such values are frequently used for functional studies in vitro. 
Thus, 25 µM fenofibrate, 25 µM bezafibrate, 40 µM troglitazone, 50 µM rosiglitazone, 50 
µM muraglitazar and 300 µM tesaglitazar represented around 1-, 8-, 50-, 35- and > 400-fold 
the therapeutic concentrations respectively (Miller and Spence, 1998; Ericsson et al., 2004; 
Wang et al., 2006; Scheen, 2007).  
Despite its relatively low expression level in the liver, PPARγ is thought to be critical in the 
development of hepatic steatosis (Desvergne et al., 2006). However, the role of PPARγ in 
NASH remains controversial. Indeed, this nuclear receptor is generally overexpressed in 
steatotic liver and has been reported to have a pro-steatogenic effect in both human and mouse 
hepatocytes (Moran-Salvador et al., 2011). Rosiglitazone was found to induce accumulation 
of neutral lipids, as detected by Oil Red O staining in the cytoplasm of primary hepatocytes 
isolated from control mice, an effect that was markedly amplified by association of 
rosiglitazone and OA (Moya et al., 2010; Moran-Salvador et al., 2011). By contrast, our 
results showed a reduction in steatosis in HepaRG cells after a 2-week treatment with 
rosiglitazone, which is in agreement with in vivo observations. Indeed, clinical studies have 
reported a reduction of steatosis after several months of treatment with rosiglitazone (Ratziu 
et al., 2008) and pioglitazone (Belfort et al., 2006). However, a systematic review and meta-
analysis of the effects of thiazolidinediones have emphasized only their modest effect in the 
improvement of patients with NASH but at the cost of significant weight gain and other 
adverse events (Musso et al., 2010; Mahady et al., 2011). Taken altogether, such variable data 
could be explained by species differences, additional in vivo effects of glitazones in non-
hepatic tissues and the use of different experimental conditions in vitro. 
 
The dual PPARα/γ agonists muraglitazar and to a lesser degree tesaglitazar, also ameliorated 
steatosis in HepaRG cells. Muraglitazar had even a stronger effect than rosiglitazone on the 
decrease in triglycerides content and induction of FAO, that could be related to its higher 
affinity for PPARγ (Fievet et al., 2006). Both glitazars have been reported to improve 
steatosis in vivo. A recent study on the effects of muraglitazar on glucose and lipid 
metabolism or fat distribution in patients has shown a beneficial effect on fat content, similar 
to that observed with pioglitazone (Fernandez et al., 2011). Tesaglitazar has been reported to 
ameliorate NAFLD in diabetic, low density receptor-deficient mice (Zhang et al., 2004) and 
to improve lipid profile in dyslipidemic patients (Tonstad et al., 2007). These two dual PPAR 
agonists were attractive as therapy for NASH and the metabolic syndrome. Unfortunately, due 
to cardiac or renal toxicities, muraglitazar and tesaglitazar were stopped during clinical trials. 
However, our results bring further support towards on-going development of new glitazars, 
such as cevoglitazar (Chen et al., 2010) and aleglitazar (Deehan et al., 2012).  
 
Fenofibrate, a PPARa agonist and bezafibrate, a PPAR pan-agonist, were also tested on 
steatotic HepaRG cells. In agreement with in vivo studies (Tonstad et al., 2007; Musso et al., 
2010; Fernandez et al., 2011; Mahady et al., 2011; Lomonaco et al., 2013), they were found 
to have less beneficial effects than rosiglitazone and glitazars on steatotic HepaRG cells. 
Indeed, despite their effectiveness in animal models (Tanaka et al., 2003; George and Liddle, 
2008) PPARa agonists have been disappointing in clinical trials. Bezafibrate has been 
reported to decrease hepatic steatosis and to increase expression of enzymes involved in FAO 
in mice (Nagasawa et al., 2006). For this drug, an involvement of PPARβ/δ is likely since 
activation of PPARβ/δ has also been reported to deplete lipid accumulation in mice (Wang et 
al., 2003). By contrast, no impact on steatosis was obtained in patients after a 12-month-
treatment with clofibrate, another PPARa agonist (Laurin et al., 1996). 
 To better understand the mechanisms involved in the decrease of triglycerides content by 
PPAR agonists, expression of several genes involved in the main lipid metabolism functions 
was analysed. Since HepaRG cells were simultaneously exposed to OA and PPAR agonists, 
both pro-steatogenic and anti-steatogenic effects could be expected at the level of gene 
expression. The PPARγ agonist rosiglitazone and especially the dual PPAR agonist 
muraglitazar, which were the most potent compounds in reducing triglycerides content and 
inducing FAO in HepaRG cells also exerted the highest effects on deregulation of several key 
genes involved in lipid metabolism, including ACOX1, CPT1A, PPARA, PPARG, ADFP, 
PLIN4, LXRA, FXR and CAR. ACOX1 and CPT1A were dramatically up-regulated from 1-
day and remained expressed at high levels after 14-day treatment, especially with 
muraglitazar. ACOX1 enzyme, which is the first and rate-limiting enzyme of the peroxisomal 
β-oxidation pathway, plays a major role in the development of hepatic steatosis in rodents 
(Fan et al., 1996) and re-expression of ACOX1 isoform  in ACOX1
-/-
 mice leads to reversal of 
hepatic steatosis (Vluggens et al., 2010). Peroxisomal β-oxidation is critical for the 
degradation of very long chain fatty acids that are not able to be degraded by the 
mitochondrial β-oxidation system. After shortening of these long-chain fatty acids, they are 
taken-up by the mitochondrial system, in which CPT1A is a major enzyme involved. 
Transcriptomic modulations were confirmed by investigation of FAO activity after treatments 
of OA-overloaded HepaRG cells with PPAR agonists. Indeed FAO activity was increased 
after 14-day repeat treatment with all PPAR agonists, especially with muraglitazar, supporting 
the view that the diminution of steatosis in HepaRG cells might be explained by a sustained 
activation of FAO. 
It is noteworthy that expression of genes encoding perilipin proteins, such as ADFP and 
PLIN4, implicated in lipid droplet formation was also up-regulated by PPAR agonist 
treatment. These two proteins are well known to coat the lipid droplets, and consequently they 
represent a marker of steatosis. Consequently, a decreased expression of ADFP and PLIN4 
would have been expected in cells treated with PPAR agonists due to the reversal of steatosis 
and diminution of triglycerides content. However, according to recent data, these two 
perilipin proteins are thought to protect non adipose cells, such as liver cells, from the 
lipotoxicity of free fatty acids by vesicle formation (Borg et al., 2009; Simard et al., 2010). 
This could explain the persistent over-expression of those perilipin proteins in steatotic 
HepaRG cells.   
As emphasized above, muraglitazar was the most effective PPAR agonist to reverse steatosis 
in HepaRG hepatocytes overloaded with OA. Analysis of the deregulated genes including 
those encoding nuclear receptors, such as LXRa, FXR and CAR, suggested that muraglitazar 
could reverse steatosis by modulation of expression of these genes. The absence of significant 
diminution of LXRa transcripts supported the view that muraglitazar had no direct effect on 
LXRa expression. However, activation and overexpression of FXR by this compound might 
result in inhibition of LXRa action, that in turn would lead to the diminution of LXRa target 
genes, such as SREBP1-c, with as a consequence a reduction of de novo lipogenesis in 
accordance with diverse recent studies showing that FXR activation could reduce LXRa 
effect and then down-regulate de novo lipogenesis (Watanabe et al., 2004; Zhang et al., 
2004).  
In addition, muraglitazar still induced CAR expression after a 14-day treatment that could 
also result in down-regulation of SREBP1c and stimulate the FAO pathway (Dong et al., 
2009). This result could be an explanation why muraglitazar was the most potent PPAR 
agonist in reducing steatosis in HepaRG cells. Further investigations of the precise effects of 
the different classes of PPAR agonists on nuclear receptors and the resulting alterations of 
lipid metabolism should allow better characterizing the mechanisms by which these agonists 
differentially reverse steatosis. 
In summary, this study represents the first analysis of the effects of diverse PPAR agonists on 
the different PPAR subtypes in steatotic human hepatocytes after repeat treatment. Its brings a 
proof of concept that drug-induced reversal of steatosis in man could be evaluated in vitro 
before conducting long-term and costly in vivo studies in animals and patients. In addition, 
our results show that although all PPAR agonists were effective dual PPARα/γ and PPARγ 
agonists appeared to be the most potent inducers of FAO and the most effective in reducing 
triglyceride accumulation in OA-overloaded HepaRG hepatocytes. These data give new 
insights in the effects of PPAR agonists on human hepatic steatosis and suggest that the 
HepaRG cell line appears suitable for a better understanding of the mechanisms involved in 
steatosis reversal, which is essential for the future development of novel and efficient 
therapeutic PPAR agonist agents for the treatment of NAFLD. 
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FIGURE LEGENDS 
 
Figure 1:  Experimental design. Human HepaRG cells were cultured for two weeks 
(proliferative phase) with an appropriate medium as described in Material and Methods, and 
then the cells were transferred to the same medium supplemented with 2% DMSO in order to 
achieve cell differentiation. The cells were rendered steatotic after a 24 h treatment by oleic 
acid (OA); then they were treated for 1 day or 14 days with the PPAR agonists.  
 
Figure 2: Determination of cell viability after PPAR agonist treatments in oleic acid-
overloaded HepaRG cells.  Cells were incubated for 24h with 250 µM oleic acid (OA) or the 
vehicle only (control) and then treated with PPAR agonists; i.e. 40 µM troglitazone (TRO), 50 
µM rosiglitazone (ROSI), 50 µM muraglitazar (MURA), 300 µM tesaglitazar (TESA), 25 µM 
fenofibrate (FENO) or 25 µM bezafibrate (BEZA) for 1 day or every 2-3 days for 14 days. 
Cytotoxicity was measured by the MTT colorimetric assay. Each point is the mean ± SEM of 
three independent experiments. All results are expressed relative to untreated control, 
arbitrarily set at the value of 100%; ns: no significant 
 
Figure 3: Determination of neutral lipid accumulation by Oil Red O staining after 
PPARs agonist treatments in oleic acid-overloaded HepaRG cells.  (A) Cells were 
incubated for 24h with 250 µM oleic acid (OA) or the vehicle only (control) and then treated 
with PPAR agonists; i.e. 40 µM troglitazone (TRO), 50 µM rosiglitazone (ROSI), 50 µM 
muraglitazar (MURA), 300 µM tesaglitazar (TESA), 25 µM fenofibrate (FENO) or 25 µM 
bezafibrate (BEZA) for 1 day or every 2-3 days for 14 days. Neutral lipids (triglycerides and 
cholesterol esters) were stained by Oil Red O and the cells were photographed with phase-
contrast microscope. Magnification 20X. (B) Quantification of Oil Red O pictures was 
realized by ImageJ software; areas of stained lipid droplets were determined for each 
condition (3 pictures per condition) and normalized by the areas of hepatocyte clusters. Each 
point is the mean ± SEM of three independent experiments. All results are expressed relative 
to untreated control, arbitrarily set at the value of 100%. #p<0.05 compared with control, 
*p<0.05 compared with OA treatment.   
Figure 4: Triglycerides quantification after PPAR agonist treatments in oleic acid-
overloaded HepaRG cells. Cells were incubated for 24h with 250 µM oleic acid (OA) or the 
vehicle only (control) and then treated with PPAR agonists; i.e. 40 µM troglitazone (TRO), 50 
µM rosiglitazone (ROSI), 50 µM muraglitazar (MURA), 300 µM tesaglitazar (TESA), 25 µM 
fenofibrate (FENO) or 25 µM bezafibrate (BEZA) for 1 day or every 2-3 days for 14 days. 
Triglycerides (TG) levels were measured by spectrophotometry after chloroform/methanol 
extraction. Each point is the mean ± SEM of three independent experiments. All results are 
expressed relative to untreated control, arbitrarily set at the value of 100%. #p<0.05 compared 
with control, *p<0.05 compared with OA treatment.   
 
Figure 5: Determination of fatty acid oxidation after PPAR agonist treatments in oleic 
acid-overloaded HepaRG cells. Cells were incubated for 24h with 250 µM oleic acid (OA) 
or the vehicle only (control) and then treated with PPAR agonists; i.e. 40 µM troglitazone 
(TRO), 50 µM rosiglitazone (ROSI), 50 µM muraglitazar (MURA), 300 µM tesaglitazar 
(TESA), 25 µM fenofibrate (FENO) or 25 µM bezafibrate (BEZA) for 1 day or every 2-3 
days for 14 days. Fatty acid oxidation (FAO) was evaluated by measuring [
14
C]-labeled acid-
soluble β-oxidation products generated by cells after a 90 minutes incubation with [
14
C]-
palmitic acid. Each point is the mean ± SEM of three independent experiments. All results are 
expressed relative to untreated control, arbitrarily set at the value of 100%. #p<0.05 compared 
with control, *p<0.05 compared with OA treatment.   
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